Australian radiopharmaceutical supplier Axiom Molecular has inked a strategic alliance to conduct PET radiopharmaceutical research, development, and commercialization activities with UniQuest, the University of Queensland's main commercialization company.
Axiom will use facilities at the university's Centre for Advanced Imaging (CAI) to produce PET radiopharmaceuticals, particularly FDG. The deal is part of Axiom's strategy to supply radiopharmaceuticals to public and private hospitals throughout Australia and the Asia-Pacific region.
Axiom has also negotiated an exclusive license to a novel radiopharmaceutical technology developed by CAI researchers, and made an equity investment in MoleQular, a startup company formed by UniQuest to develop and commercialize radiopharmaceuticals for diagnosing cancer and brain disorders.
